Pharmafile Logo
Pharmafocus logo
Advanced Search

AbbVie

Showing 15 posts of 235 posts found.

Imbruvica combo scores expanded FDA approval in most common adult form of leukaemia

January 29, 2019
Manufacturing and Production, Sales and Marketing AbbVie, Cancer, Janssen, imbruvica, leukaemia, pharma

It’s big news for Janssen and AbbVie as it emerged that their jointly-developed Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

January 25, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Celgene, NHS, health, pharma, venlytxo

While American firm AbbVie gained approval for leukaemia drug Venlytxo, the NHS defeated the US multinational thus week in court, …

News
abbvie_0

AbbVie’s case against the NHS thrown out of court

January 22, 2019
Manufacturing and Production AbbVie, HCV, NHS, health, hepatitis C, public health

A judge has thrown US multinational AbbVie’s case against NHS England’s hepatitis C procurement process, out of court. Mr Justice …

News

Abbvie’s chronic lymphocytic leukaemia drug Venclytxo scores greenlight from NICE

January 18, 2019
Medical Communications, Sales and Marketing AbbVie, NHS, NICE, Venclyxto, leukaemia, pharma

A new recommendation from NICE means that thousands of patients in England and Wales will be able to receive Abbvie’s …

News
abbvie_0

AbbVie records an estimated $4billion in impairment charges after failure of cancer drug Rova-T

January 8, 2019
Manufacturing and Production AbbVie, M&A, MA, Stemcentrx, acquisition, rova-t

US firm AbbVie has said that it will record an estimated $4 billion in impairment charges related to the abandonment …

News
abbvie_0

AbbVie’s Venclyxto combo beats standard of care in chronic lymphocytic leukaemia

December 3, 2018
Research and Development, Sales and Marketing ASH 2018, AbbVie, Cancer, Venclyxto, leukaemia, pharma

AbbVie has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to reveal new data on …

News
nhs_sign

NHS to save £300 million by switching to Humira biosimilars

November 27, 2018
Manufacturing and Production, Sales and Marketing AbbVie, Humira, Mylan, NHS, Sandoz, adalimumab, biosimilars, pharrma

NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of …

News
310px-pharmacie_in_paulista_avenue

German health minister Jens Spahn calls for faster adoption of biosimilars

November 14, 2018
Research and Development AbbVie, Germany, biosimilars, jens Spahn

Germany’s health minister Jens Spahn has called for faster uptake of biosimilars in an effort to cut the cost of …

News
abbvie_0

AbbVie sue NHS over hepatitis C drug procurement

November 8, 2018
Business Services AbbVie, NHS, britain, court, hep C, hepatitis, ruling

American pharma firm AbbVie are suing Britain’s NHS after claiming that the health service’s procurement of hepatitis C drugs breached …

News

NICE issues draft guidance rejecting Abbvie’s Venclyxto in chronic lymphocytic leukaemia

October 26, 2018
Medical Communications, Sales and Marketing AbbVie, NHS, NICE, leukaemia, pharma, venetoclax

It’s bad news for patients in the UK affected by chronic lymphocytic leukaemia (CLL) as the National Institute of Health …

News

GSK named third best UK workplace

October 22, 2018
Sales and Marketing AbbVie, Amgen, BMS, Eli Lilly, GSK, J&J, JJ, work

British multinational GlaxoSmithKline has been rated as the third best company to work for in the UK, according to jobs …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week

August 17, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, CMO, Litigation, OxyContin, Purdue Pharma, approvals, top 10

This week’s pharmaceutical headlines were dominated by legal spats as the state of New York sued OxyContin drug maker Purdue …

News
abbvie_0

Chicago Judge overturns $140 million AbbVie AndroGel verdict

August 13, 2018
Sales and Marketing AbbVie, Litigation, androgel, legal, testosterone

A US Judge has overturned a $140.1 million verdict against the New York-listed AbbVie Inc. The verdict, which ruled in …

News

FDA approves first endometriosis pain management drug in a decade

July 25, 2018
Research and Development, Sales and Marketing AbbVie, FDA, Neurocrine Biosciences, endometriosis, pharma

The FDA has confirmed its approval of AbbVie and Neurocrine Biosciences’ Orilissa (elagolix), a nonpeptide small molecule gonadotropin-releasing hormone (GnRH) …

News
humira_abbott__4

AbbVie and Mylan reach US marketing agreement for Humira biosimilar

July 18, 2018
Research and Development, Sales and Marketing AbbVie, Humira, Mylan, US, pharma

AbbVie and Mylan have announced that they have both signed a licensing agreement for the former’s proposed biosimilar version of …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026